Immune checkpoint inhibition in patients with brain metastases

Affiliations

Editorial

Tanner Johanns et al. Ann Transl Med. 2016 Oct.

. 2016 Oct;4(Suppl 1):S9.

doi: 10.21037/atm.2016.09.40.

¹ Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.

No abstract available

Conflict of interest statement

Daniel Morgensztern: Advisory board for Bristol-Myers Squibb and Celgene. The other authors have no conflicts of interest to declare.

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Goldberg SB, et al. Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3. Lancet Oncol. 2016. PMID: 27267608 Free PMC article. Clinical Trial.

1. Arvold ND, Lee EQ, Mehta MP, et al. Updates in the management of brain metastases. Neuro Oncol 2016;18:1043-65. 10.1093/neuonc/now127 - DOI - PMC - PubMed
1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012;14:48-54. 10.1007/s11912-011-0203-y - DOI - PubMed
1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72. 10.1200/JCO.2004.12.149 - DOI - PubMed
1. Callahan MK, Postow MA, Wolchok JD, Targeting T. Cell Co-receptors for Cancer Therapy. Immunity 2016;44:1069-78. 10.1016/j.immuni.2016.04.023 - DOI - PubMed
1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. 10.1016/j.immuni.2013.07.012 - DOI - PubMed